# Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.

> **NCT06630715** · — · RECRUITING · sponsor: **I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio** · enrollment: 178 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA
- Psoriatic Arthritis (PsA

## Interventions

- **DRUG:** Upadacitinib 15 MG [Rinvoq]

## Key facts

- **NCT ID:** NCT06630715
- **Lead sponsor:** I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-23
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630715, "Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06630715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*